https://www.noxopharm.com/site/PDF/2021_4/NOXReleasesLatestNewsletter
Noxopharm is aware of only two non-nucleotide STING agonists under development, intended to deliver a STING effect on a general basis but limited to cancer cells. One is the compound, MAVU-104, a pre-clinical drug candidate under development by Seattle-based Mavupharma.16 Mavupharma was acquired this week by Abbvie. The second drug candidate is Veyonda®.
Abbvie, a biopharmaceutical company with ~30,000 employees and a market cap of $102 Billion, paid an undisclosed sum for a pre-clinical compound.
Veyonda is already in the clinic and appears to selectively activate STING in humans - i.e. in cancer cells alone. I am happy to hold until someone comes knocking on our door.
Add to My Watchlist
What is My Watchlist?
